Plasma of COVID-19 patients does not alter electrical resistance of human endothelial blood-brain barrier in vitro
Preprint
Abstract
The pandemic of Coronavirus Disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) instigated the most serious global health crisis. Clinical presentation of COVID-19 frequently includes severe neurological and neuropsychiatric symptoms. However, it is presently unknown whether and to which extent pathological impairment of blood-brain barrier (BBB) contributes to the development of neuropathology during COVID-19 progression. In the present study we used human induced pluripotent stem cells-derived brain endothelial cells (iBECs) to study the effects of blood plasma derived from COVID-19 patients on the BBB integrity in vitro . We also performed a comprehensive analysis of the cytokine and chemokine profiles in the plasma of COVID-19 patients, healthy and recovered individuals. We found significantly increased levels of interferon γ-induced protein 10 kDa (IP-10), hepatocyte growth factor (HGF), and interleukin-18 (IL-18) in the plasma of COVID-19 patients. However, blood plasma from COVID-19 patients did not affect transendothelial electrical resistance (TEER) in iBEC monolayers. Our results demonstrate that COVID-19-associated blood plasma inflammatory factors do not impair BBB integrity directly and suggest that pathological remodelling of BBB during COVID-19 may occur through indirect mechanisms.Keywords
This publication has 52 references indexed in Scilit:
- Astroglial functions2023
- Neuroinflammation and COVID-19Current Opinion in Neurobiology, 2022
- Cytokine response over the course of COVID-19 infection in pregnant womenCytokine, 2022
- Concentration‐dependent duality of bFGF in regulation of barrier properties of human brain endothelial cellsJournal of Cellular Physiology, 2021
- Astrocyte–Endotheliocyte Axis in the Regulation of the Blood–Brain BarrierNeurochemical Research, 2021
- Prognostic value of interleukin-18 and its association with other inflammatory markers and disease severity in COVID-19Cytokine, 2021
- Dysregulation of the mevalonate pathway during SARS‐CoV‐2 infection: An in silico studyJournal of Medical Virology, 2020
- Frequent neurologic manifestations and encephalopathy‐associated morbidity in Covid‐19 patientsAnnals of Clinical and Translational Neurology, 2020
- Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19Journal of Allergy and Clinical Immunology, 2020
- Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, ChinaJAMA Neurology, 2020